A survey of early and advanced gastric cancer treatment by surgeons in Thailand
This study shows the first survey of patterns about surgeons ’ approaches and current practices in early and advanced gastric cancer in Thailand. Gastric cancer is a significant health problem worldwide. International guidelines for treatment differ in their recommendations including the accompanying therapy, but the condition is potentially curable. Surgeo ns have played an important role in Thailand but the limitation of institutional resources and the practices for gastric cancer vary between treatment options. The aim of this study is to investigate the current practices and approaches of Thai surgeons in relation to...
Source: Oncology Reviews - July 4, 2018 Category: Cancer & Oncology Source Type: research
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update
Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes includingRET rearrangements.RET oncogenes cannot be adequately detected by immunohistochemistry, although fluorescencein situ hybridization, reverse transcriptase polymerase chain reaction and next-generation sequencing are complementary diagnostic tools. In the clinical setting, the benefit of the most developed RET inhibitors,i.e., cabozantinb, vandetanib and le...
Source: Oncology Reviews - July 4, 2018 Category: Cancer & Oncology Source Type: research
Treat patient, not just the disease: holistic needs assessment for haematological cancer patients
Haematological malignancies can have devastating on the patients ’ physical, emotional, psycho-sexual, educational and economic health. With the improvement of therapies patients with these malignancies are living longer, however significant proportion these patient show poor quality of life (QoL) due to various physical and psychological consequences of the di sease and the treatments. Health-related QoL (HRQoL) is multi-dimensional and temporal, relating to a state of functional, physical, psychological and social/family well-being. Compared with the general population, HRQoL of these patients is worse in most dimensio...
Source: Oncology Reviews - July 4, 2018 Category: Cancer & Oncology Source Type: research
Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: Testosterone-independent malignancy is the development of prolactin-dependent malignancy!
Hormone-independent malignancy is a major issue of morbidity and deaths that confronts prostate cancer. Despite decades of research, the oncogenic and hormonal implications in the development and progression of prostate malignancy remain mostly speculative. This is largely due to the absence and/or lack of consideration by contemporary clinicians and biomedical investigators regarding the established implications of the co-regulation of testosterone and prolactin in the development, maintenance, metabolism and functions of the prostate gland. Especially relevant is the major metabolic function of production of high levels ...
Source: Oncology Reviews - July 4, 2018 Category: Cancer & Oncology Source Type: research
Myelodysplastic syndrome from theoretical review to clinical application view
Myelodysplastic syndromes (MDS), called ineffective hematopoiesis is indicated by bone marrow failure and tendency to acute myeloid leukemia transformation. Since the disease is more common in elderly with non- hematology co-morbidities, the research for less toxic and curative novel agents is essential. More than 12 years without new Food and Drug Administration approved drugs in MDS management through the whole course, only 5 drugs. We summarized the basic data in diagnosis, treatment guidelines and future direction. (Source: Oncology Reviews)
Source: Oncology Reviews - July 3, 2018 Category: Cancer & Oncology Source Type: research
HER3 signaling and targeted therapy in cancer
ERBB family members including epidermal growth factor receptor (EGFR) also known as HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in multiple cancers and hence serve as drug targets and biomarkers in modern precision therapy. The therapeutic potential of HER3 has long been underappreciated, due to impaired kinase activity and relatively low expression in tumors. However, HER3 has received attention in recent years as it is a crucial heterodimeric partner for other EGFR family members and has the potential to regulate EGFR/HER2-mediated resistance. Upregulation of HER3 is associated with several m...
Source: Oncology Reviews - May 16, 2018 Category: Cancer & Oncology Source Type: research
Cancer oriented biobanks: a comprehensive review
Biobanks provide a platform for innovative biomedical research and has improvised translational and personalized medicine to a great extent. Time 2009 published “10 ideas changing the world right now” with biobanks on the list emphasizing its role in discovery and development of new therapeutic drugs. They form the cornerstone, providing resources for future investigations and biomarker discovery to understand the effects of genetic, environmental and l ifestyle factors on human morbidity, mortality and health. The aim of this review paper is to understand the role of biobanking in cancer research, the challenges faced...
Source: Oncology Reviews - May 11, 2018 Category: Cancer & Oncology Source Type: research
Time to tame necroptosis - viable combat against chemo resistant oral cancer cells
Till 1998, a little was known about alternative forms of regulated cell death beside apoptosis. In present scenario, accumulating evidences suggest a form of programmed necrosis called Necroptosis which can be induced by various external stimuli including anticancer drugs, ionizing radiation, photodynamic therapy in the form of death domain receptor (DR) engagement by their respective ligands, TNF-alpha, Fas ligand (FasL) and TRAIL, under apoptosis deficient condition (caspase inhibitor),etc. receptor interacting protein-1 (RIP-1), a death domain containing kinase is the key molecule in necroptotic cell death pathway. On i...
Source: Oncology Reviews - March 27, 2018 Category: Cancer & Oncology Source Type: research
The impact of Mir-9 regulation in normal and malignant hematopoiesis
This study generally emphasizes on the critical role of MiR-9 in hematologic malignancies as a prognostic factor and a therapeutic target. (Source: Oncology Reviews)
Source: Oncology Reviews - March 27, 2018 Category: Cancer & Oncology Source Type: research
Saudi anti-human cancer plants database (SACPD): A collection of plants with anti-human cancer activities
Several anticancer drugs have been developed from natural products such as plants. Successful experiments in inhibiting the growth of human cancer cell lines using Saudi plants were published over the last three decades. Up to date, there is no Saudi anticancer plants database as a comprehensive source for the interesting data generated from these experiments. Therefore, there was a need for creating a database to collect, organize, search and retrieve such data. As a result, the current paper describes the generation of the Saudi anti-human cancer plants database (SACPD). The database contains most of the reported informa...
Source: Oncology Reviews - March 25, 2018 Category: Cancer & Oncology Source Type: research
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaTM) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer. (Source: Oncology Reviews)
Source: Oncology Reviews - March 21, 2018 Category: Cancer & Oncology Source Type: research
The role of pemetrexed in recurrent epithelial ovarian cancer: a scoping review
Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaTM) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer. (Source: Oncology Reviews)
Source: Oncology Reviews - March 21, 2018 Category: Cancer & Oncology Source Type: research
